Scott Weir, PharmD, Ph.D.

Professor
Director, Institute for Advancing Medical Innovation, University of Kansas
Associate Director – Translational Research, University of Kansas Cancer Center
Frank B. Tyler Cancer Reseach Professor in Therapeutic Discovery
Pharm.D., University of Nebraska College of Pharmacy, 1980
Ph.D., University of Nebraska Medical Center, 1986


Research Focus

Dr. Weir's specific areas of expertise are in clinical pharmacology, pharmacokinetics, biopharmaceutics, and developing innovative approaches to lead optimization and early drug development.  He has built a reputation of being innovative in bridging the "Valley of Death" through high performance public-private partnerships as well as repurposing approved drugs and rescuing abandoned drugs.

In addition to his faculty appointment in the department of Pharmacology, Toxicology and Therapeutics, at the University of Kansas Medical Center, Dr. Weir is the Director of the Institute for Advancing Medical Innovation (IAMI) and Associated Director - Translational Research, University of Kansas Cancer Center.  He holds a courtesy faculty appointment within Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, located on the Lawrence campus. Dr. Weir is also the Frank B. Tyler Cancer Research Professor in Therapeutic Discovery.

The Institute for Advancing Medical Innovation (IAMI), which Weir directs, conducts product development-focused translational research on products with clear paths to market. Drugs, diagnostics, and medical device applications in cancer, neuroscience, rare and neglected diseases, in children and adults, are the primary focus of IAMI.  Central to the translational research strategy of IAMI is establishing and executing projects through high performance collaborations with industry, academia, government and disease philanthropy organizations.  Weir serves on the management committee for The Learning Collaborative (TLC), a partnership between the University of Kansas, the National Center for Advancing Translational Sciences (NCATS) and The Leukemia and Lymphoma Society.  This partnership focuses on discovering and developing new treatments for blood cancers.  TLC was identified by Faster Cures as one of the top ten medical research initiatives to watch in 2012.  In early 2012, The Sarcoma Learning Collaborative (TSLC) was formed with NCATS and Children's Mercy Hospital and Clinics in Kansas City, to discover and develop new treatments for sarcomas afflicting children, adolescents, and adults.  Weir serves on the management committee for TSLC as well.

Dr. Weir has over 27 years of professional experience in the field of drug discovery and development. He joined Marion Laboratories, Inc. in 1986 as a clinical pharmacokineticist.  From the period of 1988 through 1998, Professor Weir assumed a series of management positions with increasing responsibility at Marion Laboratories, Inc, Marion Merrell Dow, Inc, Hoechst Marion Roussel, Inc and Aventis Pharmaceuticals, Inc. Over this same period, Weir was directly involved in the successful registration of several drug products such as Cardizem CD, Cardizem Injectable, Anzemet Tablets, Anzemet Injectable, Pentasa, Carafate, Rifater, and Allegra. Professor Weir was actively involved in R&D reengineering efforts for these companies in 1992 and 1997. As well, Dr. Weir led the global integration and harmonization activities for drug metabolism and pharmacokinetics during the Hoechst Marion Roussel, Inc. merger. Following sale of the North America drug development center of Hoechst Marion Roussel, Inc located in Kansas City, MO to Quintiles, Inc in January, 1999, Professor Weir managed an early drug development division which included pharmacology, toxicology, drug metabolism and pharmacokinetics, bioanalytical, and clinical pharmacology services. Dr. Weir continued these responsibilities until his departure in early 2006 to join the University of Kansas. Professor Weir has developed drug products across a wide range of therapeutic areas.                                           

In 2012, Weir was appointed by HHS Secretary Kathleen Sebelius to serve on the National Center for Advancing Translational Sciences (NCATS) Advisory Council as well as the Cures Acceleration Network (CAN) Board. 

  

Selected Publications

Jin W, Trzupek JD, Rayl TJ, Broward MA, Vielhauer GA, Weir SJ, Hwang J, and Boger DJ:  A unique class of duocarmycin and CC-1065 analogues subject to reductive activation.  J Am Chem Soc 2007 Dec 12;129(49):15391-15397. PMID:  18020335.

Weir, SJ, Patton L, Castle K, Rajewski L, Kasper H, Schimmer A:  The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of hematologic malignancy.   J Clin Pharmacy and Therapeutics, 2010;35(1):1-7. PMID:21366640. (PMC# not required; not NIH funded).

Ridwan R, Kiptoo P, Kobayashi N, Weir S, Hughes M, Williams T, et al.  Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor:  structure optimization and pharmacokinetics.  J Pharmacol Exp Ther. 2010 Mar;332(3):1136-1145. PMID:  20026673.

Lajiness JP, Robertson WM, Dunwiddie I, Broward MA, Vielhauer GA, Weir SJ, et al.  Design, synthesis and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation.  J Med Chem 2010 Nov 11;53(21):7731-8. PMID:  20942408.

Weir, SJ, Patton L, Castle K, Rajewski L, Kasper H, Schimmer A:  The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of hematologic malignancy.   J Clin Pharmacy and Therapeutics 2011 Apr;36(2):128-143. PMID:  21366640.

Sukhai MA, Spagnuolo PA, Weir S, Kasper J, Patton L, Schimmer AD. New sources of drugs for hematologic malignancies. Blood 2011 Jun 23;117(25):6747-55. PMID:  21511957.

Song, S, Christova, T, Perusini, S, Alizadesh, S, Bao, RY, Miller, BW, Hurren, R, Jitkova, Y, Gronda, M, Isaac, M, Joseph, B, Subramanian, R, Aman, A, Chau, A, Hogge, DE, Weir, SJ, Kasper, J, Schimmer, A, Al-Awar, R, Wrana, JL, Attisano, L.  Wnt inhibitor screen reveals iron dependence on {beta}-catenin signaling in cancers.  Cancer Res 2011 Oct 18 (in press).  PMID:  22009536.

Jin W, Trzupek JD, Rayl TJ, Broward MA, Vielhauer GA, Weir SJ, Hwang J, and Boger DJ:  A unique class of duocarmycin and CC-1065 analogues subject to reductive activation.  J Am Chem Soc 2007 Dec 12;129(49):15391-15397. PMID:  18020335.

Weir, SJ, DeGennaro LJ, Austin, CP.  Repurposing Approved and Abandoned Drugs for the Treatment and Prevention of Cancer through Public-Private Partnership.  Cancer Res, 2012 Mar 1;72(5):1055-8.  Epub 2012 Jan 13.  PMID:  22246671.

Kong, B, Csanaky IL, Aleksunes, LM, Patni, M, Chen, Q, Ma, X, Jaeschke, H, Weir, S, Broward, M, Klaassen, CD, Guo, GL.  Gender-specific reduction of hepatic Mrp2 expression by high-fat diet protects female mice from ANIT toxicity.  Toxicol Appl Pharmacol, 2012 Jun 1;261(2):189-195.  Epub 2012 Apr 11.  PMID:  22521610.

Subramanian, D, Periyasamy, G,  Ponnurangam, S, Chakrabarti, D, Sugumar, A, Padigaru, M, Weir, SJ, Balakrishnan, A, Sharma, S, Anant, S:  CDK-4 Inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.  Mol Cancer Ther, 2012 Jul;11(7):1598-608.  Epub 2012 Apr 24.  PMID 22532602.

Hughes, M, Inglese, J, Kurtz, A, Andalibi, A, Patton, L, Austin, C, Baltezor, M, Beckloff, M, Sittampalam, S, Weingarten, M, Weir, S:  Early Drug Discovery and Development Guidelines:  For Academic Researchers, Collaborators, and Start-Up Companies.  NCBI Bookshelf, National Library of Medicine, National Institutes of Health Bookshelf ID:  NBK92015.  Epub 2012 May 1.  PMID 22553881. 

Wolfe, AL, Duncan, KK, Parelkar, NK, Weir, SJ, Vielhauer, GA, Boger, DL:  A novel, unusally efficacious duocarmycin carbamate prodrug that releases no residual byproduct.   J Med Chem, 2012 Jun 28:55(12):5878-86.  Epub 2012 Jun 12.  PMID 22650244.  

Weir SJ, Torkin R, Henney HR.  Pharmacokinetic profile of dalframpridine extended release:  Clinical relevance in patients with MS.  Curr Med Res Opin.  Epub 2012 Nov 16.

Weir SJ, Gao Y, Henney HR. Population pharmacokinetics and pharmacodynamics of dalframpridine-ER in healthy volunteers and patients with MS.  Curr Med Res Opin.  Epub 2012 Nov 16.

Last modified: Oct 17, 2013

sweir

Contact

Scott Weir, PharmD, Ph.D.
Professor
Director, Institute for Advancing Medical Innovation, University of Kansas
Associate Director – Translational Research, University of Kansas Cancer Center
Frank B. Tyler Cancer Reseach Professor in Therapeutic Discovery

4030 Robinson; MS-1027
3901 Rainbow Blvd.
Kansas City, Kansas 66160

P: (913) 588-4798
F: (913) 588-7501
sweir@kumc.edu

ID=x9924